All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cancer type (metastatic) cancer type (recurrent) ECOG 0 ECOG 1 Gender, female Gender, male P16 negative (HPV) P16 positive (HPV) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (CPS < 1) PDL1 (CPS >1) PDL1 (TPS <50%) PDL1 (TPS >50%) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic-recurrent HNSCC (mHNSCC), anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 141, 2016 0.70 [0.51; 0.96]
EAGLE (D vs ICC), 2019 0.88 [0.72; 1.08]
KEYNOTE-040 (all population), 2018 0.80 [0.65; 0.98]
KEYNOTE-040 (CPS >1), 2018 0.74 [0.58; 0.94]
KEYNOTE-048 (P vs C ; all population), 2019 0.83 [0.70; 0.99]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.78 [0.64; 0.96]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.61 [0.45; 0.83]
KEYNOTE-048 (PC vs C ; all population), 2019 0.77 [0.63; 0.94]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.63 [0.51; 0.77]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.60 [0.44; 0.81]
0.75 [0.69 ; 0.81 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 10 19% 4,363 moderate critical deaths (OS) (extension)detailed results CheckMate 141, 2016 0.68 [0.54; 0.86]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.74 [0.61; 0.90]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.58 [0.44; 0.77]
KEYNOTE-048 (PC vs C ; all population), 2019 0.72 [0.60; 0.87]
0.70 [0.62 ; 0.77 ] CheckMate 141, 2016, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 0% 1,687 moderate not evaluable PFS (extension)detailed results CheckMate 141, 2016 0.87 [0.68; 1.11]
0.87 [0.68 ; 1.11 ] CheckMate 141, 2016 1 0% 361 NA not evaluable progression or deaths (PFS)detailed results CheckMate 141, 2016 0.89 [0.70; 1.13]
EAGLE (D vs ICC), 2019 1.02 [0.84; 1.24]
KEYNOTE-040 (all population), 2018 0.96 [0.79; 1.16]
KEYNOTE-040 (CPS >1), 2018 1.01 [0.81; 1.26]
KEYNOTE-048 (P vs C ; all population), 2019 1.34 [1.13; 1.59]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 1.16 [0.96; 1.40]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.99 [0.75; 1.30]
KEYNOTE-048 (PC vs C ; all population), 2019 0.92 [0.77; 1.10]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.82 [0.67; 1.00]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.73 [0.55; 0.97]
0.98 [0.88 ; 1.10 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 10 63% 4,363 moderate critical DCRdetailed results EAGLE (D vs ICC), 2019 1.00 [0.63; 1.58]
1.00 [0.63 ; 1.58 ] EAGLE (D vs ICC), 2019 1 0% 489 NA not evaluable objective responses (ORR)detailed results CheckMate 141, 2016 2.51 [1.07; 5.86]
EAGLE (D vs ICC), 2019 1.05 [0.66; 1.68]
KEYNOTE-040 (all population), 2018 1.52 [0.88; 2.62]
KEYNOTE-040 (CPS >1), 2018 1.90 [1.04; 3.47]
KEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.25; 0.53]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.44 [0.29; 0.66]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.11 [0.06; 0.20]
KEYNOTE-048 (PC vs C ; all population), 2019 0.97 [0.69; 1.37]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 1.03 [0.71; 1.49]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 1.21 [0.72; 2.05]
0.82 [0.50 ; 1.33 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 10 91% 4,372 moderate low objective responses (ORR) (extension)detailed results CheckMate 141, 2016 2.51 [1.07; 5.86]
2.51 [1.07 ; 5.86 ] CheckMate 141, 2016 1 0% 361 NA not evaluable AE (any grade)detailed results EAGLE (D vs ICC), 2019 0.45 [0.21; 0.94]
KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.22; 0.44]
0.33 [0.24 ; 0.45 ] EAGLE (D vs ICC), 2019, KEYNOTE-048 (P vs C ; all population), 2019 2 0% 1,064 moderate not evaluable AE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.89 [0.62; 1.28]
KEYNOTE-048 (PC vs C ; all population), 2019 1.00 [0.69; 1.46]
0.94 [0.73 ; 1.22 ] EAGLE (D vs ICC), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,040 moderate not evaluable AE leading to death (grade 5)detailed results EAGLE (D vs ICC), 2019 1.01 [0.52; 1.97]
KEYNOTE-048 (P vs C ; all population), 2019 0.84 [0.48; 1.48]
KEYNOTE-048 (PC vs C ; all population), 2019 1.21 [0.71; 2.07]
1.02 [0.73 ; 1.42 ] EAGLE (D vs ICC), 2019, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 0% 1,627 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results EAGLE (D vs ICC), 2019 0.97 [0.53; 1.77]
KEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.23; 0.55]
KEYNOTE-048 (PC vs C ; all population), 2019 1.27 [0.89; 1.83]
0.76 [0.33 ; 1.74 ] EAGLE (D vs ICC), 2019, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 90% 1,627 moderate not evaluable SAE (any grade)detailed results EAGLE (D vs ICC), 2019 1.21 [0.80; 1.80]
1.21 [0.80 ; 1.80 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable STRAE (any grade)detailed results EAGLE (D vs ICC), 2019 1.16 [0.56; 2.38]
1.16 [0.56 ; 2.38 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable TRAE (any grade)detailed results CheckMate 141, 2016 0.31 [0.18; 0.52]
EAGLE (D vs ICC), 2019 0.29 [0.19; 0.45]
KEYNOTE-040 (all population), 2018 0.33 [0.21; 0.51]
KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.02; 0.09]
KEYNOTE-048 (PC vs C ; all population), 2019 0.71 [0.30; 1.72]
0.25 [0.13 ; 0.49 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 5 87% 2,454 moderate not evaluable TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.35 [0.21; 0.59]
KEYNOTE-040 (all population), 2018 0.24 [0.15; 0.39]
KEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.06; 0.13]
KEYNOTE-048 (PC vs C ; all population), 2019 1.12 [0.78; 1.61]
0.31 [0.10 ; 0.97 ] EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 97% 2,107 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 141, 2016 0.94 [0.08; 10.48]
EAGLE (D vs ICC), 2019 8.22 [0.43; 156.41]
KEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57]
KEYNOTE-048 (P vs C ; all population), 2019 0.35 [0.09; 1.34]
KEYNOTE-048 (PC vs C ; all population), 2019 1.45 [0.57; 3.65]
1.15 [0.51 ; 2.61 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 5 25% 2,454 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 141, 2016 0.45 [0.18; 1.11]
EAGLE (D vs ICC), 2019 0.91 [0.36; 2.28]
KEYNOTE-040 (all population), 2018 1.20 [0.55; 2.62]
0.81 [0.46 ; 1.45 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018 3 25% 1,304 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.28 [0.53; 3.10]
1.28 [0.53 ; 3.10 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
0.67 [0.06 ; 7.40 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.94 [0.03; 28.25]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.18 [0.19 ; 7.27 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 0% 1,977 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.98 [0.06 ; 15.74 ] EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018 2 0% 957 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.06; 0.92]
EAGLE (D vs ICC), 2019 0.04 [0.00; 0.75]
KEYNOTE-040 (all population), 2018 0.10 [0.01; 0.81]
KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.01; 0.16]
KEYNOTE-048 (PC vs C ; all population), 2019 1.38 [0.89; 2.14]
0.16 [0.03 ; 0.96 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 5 88% 2,454 moderate serious Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.02; 2.59]
EAGLE (D vs ICC), 2019 0.50 [0.05; 5.60]
KEYNOTE-040 (all population), 2018 0.23 [0.03; 2.12]
KEYNOTE-048 (P vs C ; all population), 2019 0.16 [0.02; 1.31]
KEYNOTE-048 (PC vs C ; all population), 2019 1.22 [0.40; 3.67]
0.52 [0.22 ; 1.23 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 5 9% 2,454 moderate serious Blood and lymphatic system disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.04 [0.01; 0.31]
KEYNOTE-048 (P vs C ; all population), 2019 0.02 [0.01; 0.07]
KEYNOTE-048 (PC vs C ; all population), 2019 1.30 [0.92; 1.82]
0.12 [0.01 ; 2.59 ] KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 97% 1,630 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
1.30 [0.15 ; 11.18 ] KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 0% 1,630 moderate not evaluable Cardiac disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Chills TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.13; 6.84]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.15; 7.44]
0.92 [0.27 ; 3.19 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 0% 1,977 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
0.74 [0.09 ; 6.36 ] KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 0% 1,630 moderate not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.17 [0.01; 3.35]
KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
KEYNOTE-048 (P vs C ; all population), 2019 0.12 [0.01; 0.94]
KEYNOTE-048 (PC vs C ; all population), 2019 1.59 [0.64; 3.94]
0.56 [0.12 ; 2.67 ] EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 54% 2,107 moderate not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
1.01 [0.02 ; 51.25 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
EAGLE (D vs ICC), 2019 0.17 [0.01; 3.35]
KEYNOTE-040 (all population), 2018 3.85 [0.43; 34.71]
KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62]
KEYNOTE-048 (PC vs C ; all population), 2019 0.62 [0.15; 2.62]
0.49 [0.15 ; 1.57 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 5 28% 2,454 moderate not evaluable Dyspepsia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 3.83 [0.17; 85.33]
3.83 [0.17 ; 85.33 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.94 [0.03; 28.25]
KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
KEYNOTE-048 (P vs C ; all population), 2019 5.79 [0.29; 116.06]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.30 [0.45 ; 11.90 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 0% 1,977 moderate not evaluable Epistaxis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
0.23 [0.01 ; 7.01 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Eye disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.78 [0.18; 3.32]
EAGLE (D vs ICC), 2019 1.01 [0.14; 7.25]
KEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57]
KEYNOTE-048 (P vs C ; all population), 2019 0.25 [0.07; 0.92]
KEYNOTE-048 (PC vs C ; all population), 2019 1.85 [0.87; 3.97]
0.96 [0.42 ; 2.18 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 5 46% 2,454 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.05 [0.00; 0.79]
0.05 [0.00 ; 0.79 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Gastritis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.23 [0.02; 2.59]
KEYNOTE-040 (all population), 2018 0.35 [0.14; 0.86]
KEYNOTE-048 (P vs C ; all population), 2019 0.07 [0.02; 0.23]
0.18 [0.06 ; 0.57 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019 3 56% 1,414 moderate not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.57 [0.23; 1.40]
KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.08; 0.46]
KEYNOTE-048 (PC vs C ; all population), 2019 1.90 [1.15; 3.13]
0.61 [0.15 ; 2.52 ] KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 90% 1,630 moderate not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
0.47 [0.02 ; 14.21 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 2.01 [0.07; 60.26]
KEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.59 [0.39 ; 17.34 ] KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 0% 1,645 moderate not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.94 [0.08; 10.48]
KEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29]
0.94 [0.15 ; 5.84 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.43 [0.03 ; 5.58 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Hypertension TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.02 [0.16 ; 6.74 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 0% 1,977 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.94 [0.03; 28.25]
KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
1.55 [0.22 ; 11.07 ] CheckMate 141, 2016, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 0% 1,497 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.04 [0.16 ; 6.83 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (PC vs C ; all population), 2019 4 0% 1,867 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 0.31 [0.03; 3.04]
0.35 [0.05 ; 2.48 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.03; 7.55]
EAGLE (D vs ICC), 2019 1.01 [0.06; 16.29]
KEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15]
0.44 [0.09 ; 2.29 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018 3 0% 1,304 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 141, 2016 3.81 [0.20; 72.71]
3.81 [0.20 ; 72.71 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
KEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29]
KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.06; 1.57]
KEYNOTE-048 (PC vs C ; all population), 2019 0.34 [0.07; 1.71]
0.37 [0.13 ; 1.00 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 0% 1,977 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.08 [0.00; 1.54]
EAGLE (D vs ICC), 2019 0.12 [0.01; 2.37]
KEYNOTE-040 (all population), 2018 0.07 [0.00; 1.17]
KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.51 [0.21; 1.20]
0.16 [0.04 ; 0.56 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 5 36% 2,454 moderate serious Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
0.47 [0.04 ; 6.17 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.40 [0.10; 1.57]
KEYNOTE-048 (P vs C ; all population), 2019 0.26 [0.14; 0.49]
KEYNOTE-048 (PC vs C ; all population), 2019 0.88 [0.55; 1.41]
0.47 [0.19 ; 1.17 ] KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 79% 1,630 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.51 [0.02; 15.13]
KEYNOTE-040 (all population), 2018 0.19 [0.02; 1.61]
KEYNOTE-048 (P vs C ; all population), 2019 0.13 [0.03; 0.58]
KEYNOTE-048 (PC vs C ; all population), 2019 2.03 [1.04; 3.97]
0.44 [0.08 ; 2.55 ] EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 78% 2,107 moderate not evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
1.49 [0.11 ; 19.48 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.48 [0.02; 14.29]
KEYNOTE-048 (PC vs C ; all population), 2019 0.52 [0.02; 15.54]
0.50 [0.05 ; 5.51 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
EAGLE (D vs ICC), 2019 2.03 [0.07; 60.79]
KEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21]
KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.97 [0.47; 2.01]
0.45 [0.11 ; 1.82 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 5 39% 2,454 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
2.32 [0.20 ; 26.51 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Nervous system disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.47 [0.04; 5.26]
0.47 [0.04 ; 5.26 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.04 [0.00; 0.68]
KEYNOTE-040 (all population), 2018 0.04 [0.01; 0.33]
KEYNOTE-048 (P vs C ; all population), 2019 0.01 [0.00; 0.11]
KEYNOTE-048 (PC vs C ; all population), 2019 0.85 [0.56; 1.30]
0.07 [0.01 ; 0.86 ] EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 87% 2,107 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.23 [0.01; 7.01]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.43 [0.03 ; 5.58 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
1.49 [0.11 ; 19.48 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Pancytopenia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15]
0.16 [0.01 ; 3.15 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 0.50 [0.05; 5.60]
0.50 [0.05 ; 5.60 ] EAGLE (D vs ICC), 2019 1 0% 477 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.91 [0.06 ; 57.09 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 141, 2016 1.89 [0.08; 42.24]
KEYNOTE-040 (all population), 2018 3.83 [0.17; 85.33]
KEYNOTE-048 (P vs C ; all population), 2019 2.42 [0.46; 12.55]
KEYNOTE-048 (PC vs C ; all population), 2019 2.63 [0.51; 13.67]
2.56 [0.91 ; 7.16 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 0% 1,977 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pruritus generalised TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
KEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27]
0.43 [0.05 ; 3.39 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018 3 0% 1,304 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.26 [0.02 ; 2.98 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Rash TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 1.01 [0.02; 51.25]
KEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29]
KEYNOTE-048 (P vs C ; all population), 2019 0.11 [0.02; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.06 [0.01; 0.44]
0.16 [0.05 ; 0.54 ] EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 18% 2,107 moderate not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09]
1.05 [0.08 ; 13.66 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 1.89 [0.08; 42.24]
KEYNOTE-040 (all population), 2018 1.44 [0.40; 5.16]
1.50 [0.46 ; 4.88 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Sepsis TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27]
0.24 [0.01 ; 5.27 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.54 [0.15; 1.86]
KEYNOTE-048 (P vs C ; all population), 2019 0.29 [0.11; 0.73]
KEYNOTE-048 (PC vs C ; all population), 2019 0.10 [0.02; 0.45]
0.27 [0.12 ; 0.61 ] KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 30% 1,630 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
KEYNOTE-040 (all population), 2018 0.31 [0.08; 1.15]
KEYNOTE-048 (PC vs C ; all population), 2019 0.11 [0.03; 0.35]
0.17 [0.07 ; 0.39 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (PC vs C ; all population), 2019 3 0% 1,390 moderate not evaluable Skin exfoliation TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.67 [0.04 ; 10.72 ] CheckMate 141, 2016, KEYNOTE-040 (all population), 2018 2 0% 827 moderate not evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results EAGLE (D vs ICC), 2019 2.03 [0.07; 60.79]
KEYNOTE-040 (all population), 2018 0.08 [0.01; 0.65]
KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.00; 0.80]
KEYNOTE-048 (PC vs C ; all population), 2019 2.40 [1.11; 5.16]
0.40 [0.04 ; 3.88 ] EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 4 80% 2,107 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.12 [0.01; 2.59]
EAGLE (D vs ICC), 2019 1.01 [0.06; 16.29]
KEYNOTE-040 (all population), 2018 0.09 [0.01; 1.72]
KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.00; 0.27]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.58; 1.89]
0.25 [0.05 ; 1.29 ] CheckMate 141, 2016, EAGLE (D vs ICC), 2019, KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 5 70% 2,454 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
0.78 [0.08 ; 7.48 ] CheckMate 141, 2016, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 0% 1,497 moderate not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 141, 2016 0.47 [0.01; 23.80]
0.47 [0.01 ; 23.80 ] CheckMate 141, 2016 1 0% 347 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.00 [0.06 ; 15.99 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Vascular disorders TRAE (grade 3-4)detailed results KEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13]
0.95 [0.02 ; 48.13 ] KEYNOTE-040 (all population), 2018 1 0% 480 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.01; 1.73]
KEYNOTE-048 (PC vs C ; all population), 2019 1.47 [0.46; 4.68]
0.52 [0.04 ; 7.08 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 66% 1,150 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 03:07 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 276,103,277,102,109,278,101,192,114
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563